{Reference Type}: Journal Article
{Title}: Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations.
{Author}: Zhou S;Long N;Rosenke K;Jarvis MA;Feldmann H;Swanstrom R;
{Journal}: J Infect Dis
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 8
{Factor}: 7.759
{DOI}: 10.1093/infdis/jiae213
{Abstract}: We investigated the mutation profiles of severe acute respiratory syndrome coronavirus 2 in samples collected from a molnupiravir and nirmatrelvir/ritonavir combination therapy in macaques. We found that molnupiravir induced several nirmatrelvir resistance mutations at low abundance that were not further selected in combination therapy. Coadministration of nirmatrelvir/ritonavir lowered the magnitude of the mutagenetic effect of molnupiravir.